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Abstract
Objective—To study anti-Ro/La-negative congenital heart block (CHB).
Methods—Forty-five fetuses with CHB were evaluated by analysis of anti-Ro/La antibodies using
sensitive laboratory methods.
Results—There were 9 cases of anti-Ro/La-negative CHB; 3 died (33.3%). Only 3 (33.3%) were
complete in utero and 5 (55.5%) were unstable. No specific etiology was diagnosed. Six infants
(66.6%) were given pacemakers. There were 36 cases of anti-Ro/La-positive CHB. All except 2
infants (94.4%) had complete atrioventricular block in utero. Ten died (27.8%), one (2.7%)
developed severe dilated cardiomyopathy, and 26 (72.2%) were given pacemakers.
Conclusion—Nine of the 45 consecutive CHB cases (20%) were anti-Ro/La-negative with no
known cause. They were less stable and complete than the anti-Ro/La positive cases.
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Most cases of congenital heart block (CHB) detected in utero and unrelated to structural cardiac
abnormalities are associated with anti-Ro/La antibodies, although the percentages of positive
cases vary1–5. Descriptions of the prevalence and outcome of anti-Ro/La-negative
atrioventricular (AV) block also tend to differ2–10. According to some investigators, mortality
and morbidity are similar to those in anti-Ro/La-positive AV block3,4,7,8, while others report
spontaneously reversible CHB and a more favorable course6,9,10.
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MATERIALS AND METHODS
Forty-five consecutive fetuses with AV block were observed from 1990 to 2007 in 5 tertiary
referral centers in Northern Italy (2 rheumatological, 2 cardiological, and one obstetric clinic).
The inclusion criteria were congenital AV block detected in utero or at birth by fetal
echocardiography and electrocardiogram. The exclusion criteria were structural cardiac
abnormalities, congenital long QT syndrome11, mothers who had taken drugs during pregnancy
that could induce fetal bradycardia, mothers who had had infectious diseases during pregnancy,
or who had tested positive to hepatitis B/C viruses or human immunodeficiency virus, or to
IgM anticytomegalovirus, Herpes or rubella virus and toxoplasma at the beginning of
pregnancy.
Maternal sera were collected when CHB was detected and at delivery and tested for
autoantibodies to Ro/SSA and La/SSB ribonucleoproteins using ELISA. Sera were tested a
second time at the Padua University Hospital rheumatology laboratory employing a custom-
designed counter-immunoelectrophoresis (CIE) method12; the fine specificities for 52-kDa and
60-kDa anti-Ro/SSA and 48-kDa anti-La/SSB were determined using a commercial ELISA
(Diamedix, Delta Biologicals, Rome, Italy) and a line-blot assay (Inno-Lia, Innogenetics,
Ghent, Belgium). Maternal sera negative to anti-Ro/SSA and anti-La/SSB antibodies were
tested for confirmation by immunoblotting analysis using human salivary gland cell lysates,
by ELISA using recombinant Ro52 protein, and by immunoprecipitation analysis with Ro60
and La in vitro translated proteins13, all at the laboratory of the University of Florida
Department of Oral Biology. Maternal sera were also tested at the Padua laboratory for a battery
of autoantibodies, including antinuclear (ANA), anti-dsDNA, anti-extractable nuclear antigens
(ENA), anticardiolipin, and anti-β2-glycoprotein I antibodies.
Statistical analysis was done using SPSS software, version 14.0.
RESULTS
Forty-five fetuses with CHB were examined. Thirty-six were born to anti-Ro/La-positive
mothers (80%) and 9 to anti-Ro/La-negative mothers (20%). Negative maternal sera lacked
reactivity to both Ro/SSA and La/SSB according to ELISA, CIE, and line-blot assays. These
results were confirmed by the University of Florida Department of Oral Biology.
Anti-Ro/La-negative CHB infants (Table 1)
Five (55.5%) of the 9 infants were female. Three developed complete AV block in utero
(Patients 1, 2, 3) and one also presented congenital sensorineural deafness. Two others had a
stable second-degree AV block (Patients 4 and 5). Two fetuses had a second-degree AV block,
one progressing to complete block soon after birth and the other at 3 months (Patients 6 and
7). The block alternated with normal sinus rhythm in the other 2 infants (Patients 8 and 9) and
reverted to a stable normal sinus rhythm in Patient 9. Five blocks were unstable, changing their
degree (nos 3,6,7,8,9).
Six blocks (66.6%) were detected in utero Three (33.3%) were diagnosed at birth (Table 1 and
2) when cesarean delivery was needed because of fetal bradycardia. Six were given
pacemakers. Two presented signs of heart failure in utero and 3 died (33.3%) shortly after
birth. The 6 survivors had a mean age of 5.5 ± 3.5 years at the end of followup.
Echocardiography showed no signs of cardiomyopathy or myocarditis.
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Anti-Ro/La-negative mothers
Eight mothers were asymptomatic and one had photosensitivity and Raynaud’s phenomenon.
All were negative for ANA, anti-dsDNA, anti-ENA, and antiphospholipid antibody. Eight had
further pregnancies, with no recurrences. One had a family history of AV block (11.1%).
Anti-Ro/La-positive CHB infants (Table 3)
Twenty-five (69.4%) cases were female. None of the 34 presenting with complete AV block
in utero reverted to a lesser degree (Table 2 and 3), but the 2 infants with incomplete block
did. One of the fetuses with a second-degree AV block reverted to a normal sinus rhythm after
therapy with high-dose dexamethasone and was born with a first-degree block that remained
stable throughout the followup. The other fetus, with a second-degree AV block, reverted to
an alternating pattern between second-degree block and normal sinus rhythm during treatment
with dexamethasone 4 mg daily and weekly plasmapheresis; at age 27 months she developed
a complete AV block.
AV block was always diagnosed in utero on the basis of fetal bradycardia (mean gestational
age 23.03 weeks). There were 2 cases of sudden death in utero and 4 were aborted, 3 with
severe heart failure. Three died immediately after birth due to heart failure and a fourth, who
was given a pacemaker shortly after birth, died suddenly at age 21 months. Twenty-six neonates
(72.2%) were given a pacemaker (Table 2 and 3); 4 of them died. Twenty-six infants were
alive at the end of the followup, with mean age 6.6 ± 4.5 years. Echocardiography showed
myocarditis in utero in 2 cases (5.5%). One male received a heart transplant at age 17 months
because of severe dilated cardiomyopathy.
Anti-Ro/La-positive mothers
Eleven mothers were asymptomatic; 12 had Sjögren’s syndrome, 11 undifferentiated
connective tissue disease, and 2 systemic lupus erythematosus. Thirteen (36.1%) were anti-
La/SSB-positive. Only 4 had been diagnosed with connective tissue disease before the index
pregnancy. Twelve had further pregnancies and there were no recurrences. There was a family
history in one case (2.7%)14.
DISCUSSION
Cardiologists have been skeptical in the past about the existence of immune-mediated CHB,
and some rheumatologists may still be doubtful about the existence of CHB not associated
with anti-Ro/La antibodies. The exact percentages of anti-Ro/La antibody positivity in mothers
of fetuses with CHB detected in utero and not associated with structural cardiac abnormalities
are not known. Immunological studies using the most sensitive laboratory methods give
positive results close to 100%, but these mothers were selected mainly from rheumatology
centers2. Cardiological studies report lower percentages of anti-Ro/La-positive cases but do
not always provide details about the laboratory methods3,6–10. Schmidt, et al3 and Maeno, et
al7 reported 35% of anti-Ro/La negativity but did not indicate the laboratory tests. Using
Ouchterlony double-diffusion and quantitative radio-ligand assays, Villain, et al5 reported that
55/111 cases (49.5%) of complete AV block detected before age 15 years were anti-Ro/La-
negative. They also reported that 6/56 blocks (10.7%) detected in utero were anti-Ro/La-
negative, and another 25 had to be excluded because their antibody status was not known5.
Lopes, et al15 reported that 41/57 (71.9%) mothers of fetuses with isolated AV block “were
seropositive for antinuclear antibodies, most often anti-Ro antibodies,” but did not indicate the
test method. In agreement with our findings that report showed that spontaneous regression of
AV block was possible in cases of anti-Ro/SSA-negative block and that mortality was similar
in anti-Ro/SSA-positive and negative blocks, so these blocks too call for close followup.
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Referral and ascertainment bias might have skewed our results. However, we used state of the
art laboratory methods and took the extra step of investigating further the initially negative
reactivity for anti-Ro/SSA and La/SSB. In fact there were concerns that the negative reactivity
was the result of low sensitivity of some assays or of failure to detect conformational epitopes
(e.g., Ro60), which are readily detectable with immunoprecipitation of radiolabeled
recombinant Ro60. By including these extra steps, we are confident about the negative
reactivity reported here.
It has been suggested that cases of complete in utero AV block are often anti-Ro/La-positive,
while incomplete blocks are generally negative5,6,8–10. Our study is the first to specifically
compare anti-Ro/La-negative CHB with positive cases (Table 2) using sensitive laboratory
methods. Twenty percent of our consecutive CHB cases were negative, but only 8.1% were
negative when the analysis was limited to AV blocks that became complete in utero.
As no definite etiology (such as tumors, myocarditis, drugs) was found in the cases of anti-Ro/
La-negative CHB, these must be considered “idiopathic.” It is possible that there was some
viral involvement, but it goes beyond the aims of our study to assess the role of viruses in the
pathogenesis of CHB, whether anti-Ro/La-positive or negative. That one anti-Ro/La-negative
female infant presented congenital sensorineural deafness is an interesting finding that warrants
further study, since it has been correlated with congenital long QT syndrome11.
The early diagnosis of Ro/La-positive CHB cannot be explained by the fact that the mothers
were attending rheumatology centers, as 32 of the 36 mothers were unknown to us before the
blocks were detected.
The mortality rate was similar in the anti-Ro/La-negative and positive groups (33.3% and
27.8%, respectively), in agreement with Lopes, et al15, but the causes were different. No anti-
Ro/La-negative fetuses developed cardiomyopathy. The cardiological courses of the cases of
negative blocks were partially different for later gestational age and because they presented
less often as complete, but often had a changing or progressive course.
While these findings have all the limitations of an observational study, there can be no doubt
about the antibody negativity of the 9 cases we found. Although no single variable clearly
distinguished Ro/La-positive from negative cases of CHB, the latter were often incomplete,
were detected later during pregnancy, and were less stable.
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Table 2
Comparison of anti-Ro/La-positive (n = 36) and anti-Ro/La-negative (n = 9) CHB.
Ro/La-positive Ro/La-negative Method p*
Total deaths (%) 10 (27.78) 3 (33.33) Fisher 0.384**
Male/female 11/25 4/5 Fisher 0.454
Mean gestational age at
detection, wks
23.03 ± 3.90 30.56 ± 7.30 U test 0.005
Mean lowest fetal HR (bpm) 57.17 ± 11.92 62.89 ± 24.93 U test 0.628
Mean gestational age at
delivery, wks
34.67 ± 3.41 35.67 ± 3.53 t test 0.400
Mean weight at birth, g 2168.67 ± 606.61 2567.78 ± 659.05 t test 0.098
Mean length at birth, cm 38.16 ± 8.15 44.44 ± 5.98 U test 0.073
Mean Apgar 1 min 7.63 ± 2.24 7.44 + 1.24 U test 0.241
Mean Apgar 5 min 8.71 ± 1.52 8.78 ± 1.00 U test 0.433
Mean HR at birth (bpm) 59.20 ± 21.13 70.67 ± 27.82 U test 0.165
Incomplete AV block at end
of followup (%)
1 (2.78) 4 (44.44) Fisher 0.004
AV block complete in utero
(%)
34 (94.44) 3 (33.33) Fisher 0.000
AV block detected at birth
(%)
0 3 (33.33) Fisher 0.006
Pacemaker (%) 26 (72.22) 6 (66.67) Fisher 0.704
Mean age at pacemaker
insertion, days
454.12 ± 1056.89 87.83 ± 142.93 U test 0.497
Asymptomatic mothers (%) 11 (30.55) 8 (88.89) Fisher 0.002
*
Significant at p < 0.05.
**
To calculate this p value the 4 terminations are considered as missing values. AV: atrioventricular; Fisher: Fisher’s exact
test.
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